Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ethan O Perlstein

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Disease Models & Mechanisms|October 17, 2019
Drug screens of <i>NGLY1</i> deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approachesSangeetha Iyer, Joshua D Mast, Hillary Tsang, et al.
Glycobiology|October 3, 2024
N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblastsKishore Garapati, Wasantha Ranatunga, Neha Joshi, et al.
Disease Models & Mechanisms|October 23, 2019
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Feba S Sam, Nina DiPrimio, et al.
Nature Chemical Biology|May 9, 2007
Small molecules enhance autophagy and reduce toxicity in Huntington's disease modelsSovan Sarkar, Ethan O Perlstein, Sara Imarisio, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDGHiba Daghar, Seul Kee Byeon, Claudia Maios, et al.
International Journal of Molecular Sciences|August 12, 2022
Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)Sandra Brasil, Mariateresa Allocca, Salvador C M Magrinho, et al.
Neuron|August 12, 2022
Glial control of sphingolipid levels sculpts diurnal remodeling in a circadian circuitJohn P Vaughen, Emma Theisen, Irma Magaly Rivas-Serna, et al.
Annals of Neurology|October 15, 2021
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic ImplicationsAnna N Ligezka, Silvia Radenkovic, Mayank Saraswat, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Disease Models & Mechanisms|October 17, 2019
Drug screens of <i>NGLY1</i> deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approachesSangeetha Iyer, Joshua D Mast, Hillary Tsang, et al.
Glycobiology|October 3, 2024
N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblastsKishore Garapati, Wasantha Ranatunga, Neha Joshi, et al.
Disease Models & Mechanisms|October 23, 2019
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDGSangeetha Iyer, Feba S Sam, Nina DiPrimio, et al.
Nature Chemical Biology|May 9, 2007
Small molecules enhance autophagy and reduce toxicity in Huntington's disease modelsSovan Sarkar, Ethan O Perlstein, Sara Imarisio, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Repurposing the HMG-CoA Reductase Inhibitor Atorvastatin for SRD5A3-CDGHiba Daghar, Seul Kee Byeon, Claudia Maios, et al.
International Journal of Molecular Sciences|August 12, 2022
Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)Sandra Brasil, Mariateresa Allocca, Salvador C M Magrinho, et al.
Neuron|August 12, 2022
Glial control of sphingolipid levels sculpts diurnal remodeling in a circadian circuitJohn P Vaughen, Emma Theisen, Irma Magaly Rivas-Serna, et al.
Annals of Neurology|October 15, 2021
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic ImplicationsAnna N Ligezka, Silvia Radenkovic, Mayank Saraswat, et al.
Pageof 3